LIORESAL

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Italy, Japan, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug LIORESAL contains one active pharmaceutical ingredient (API):

1	Baclofen UNII H789N3FKE8 - BACLOFEN
	Baclofen depresses monosynaptic and polysynaptic reflex transmission, probably by stimulating the GABAB-receptors. This stimulation in turn inhibits the release of the excitatory amino acids glutamate and aspartate. Neuromuscular transmission is unaffected by baclofen. Baclofen also exerts an antinociceptive effect.
	Read more about Baclofen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIORESAL Solution for intrathecal injection / infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M03BX01	Baclofen	M Musculo-skeletal system → M03 Muscle relaxants → M03B Muscle relaxants, centrally acting agents → M03BX Other centrally acting agents
Discover more medicines within M03BX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2729P, 2730Q, 5617P, 6284R
BR	Câmara de Regulação do Mercado de Medicamentos	526508601113419
CA	Health Products and Food Branch	02131048, 02131056, 02131064
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	02181224, 02181230, 02181247, 02499920, 02499937, 02499943, 03012067, 03012073, 03463700, 03463717, 03686831, 03686877, 04959194, 04959219, 08874833
EE	Ravimiamet	1600782, 1623710, 1651508, 1665705, 1668113, 1753815, 1754478, 1769700, 1791222, 1803057
ES	Centro de información online de medicamentos de la AEMPS	52180, 52181, 62346, 62347, 62348
FI	Lääkealan turvallisuus- ja kehittämiskeskus	448670, 448688
FR	Base de données publique des médicaments	60304050, 62311182, 65317023, 69375846
GB	Medicines & Healthcare Products Regulatory Agency	143008, 20024, 241200, 36264, 36268, 36271
HK	Department of Health Drug Office	00226, 51460
HR	Agencija za lijekove i medicinske proizvode	HR-H-455944140, HR-H-786110495
IE	Health Products Regulatory Authority	39535, 59765
IT	Agenzia del Farmaco	022999027
JP	医薬品医療機器総合機構	1249006F1054, 1249006F2042
NL	Z-Index G-Standaard, PRK	16756, 2607
NZ	Medicines and Medical Devices Safety Authority	13522, 13523
PL	Rejestru Produktów Leczniczych	100160730, 100160746, 100224370, 100262984, 100293737, 100390765, 100423789, 100423795, 100456060, 100460776, 100461375, 100464044
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W10193001, W10193002, W10194001
SG	Health Sciences Authority	05330P
TN	Direction de la Pharmacie et du Médicament	10283081
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504010077
US	FDA, National Drug Code	70257-560, 70257-561, 70257-562, 70257-563
ZA	Health Products Regulatory Authority	E/2.10/227, E/2.10/228